efficacy and adverse events in 2 different SLIT tablets for house dust mite allergy

efficacy and adverse events in 2 different SLIT tablets for house dust mite allergy - efficacy and safety in SLIT tablets

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021195

Enrollment

Registered

2017-04-01

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

house dust mite - nasal allergy

Interventions

actair treatment group miticure treatment group control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: house-dust-mite allergic rhinitis

Exclusion criteria

Exclusion criteria: pregnant at the start of treatment patients who suffered from malignancy and/or connective tissue disase patinents who have uncontrolled athma patients who have severe heart diseases or stroke patients who are prescribed beta-antatonisit patnets who are prescribed oral steroid (5mg>=)

Design outcomes

Primary

Measure	Time frame
nasal symptom score, medication score, symptom-medication score, QOL, adverse events	—

Secondary

Measure	Time frame
process of HDM sepecific IgE, IgG4 during and after SLIT novel allergen sensitaization, asthma prevalence rate after SLIT	—

Countries

Japan

Contacts

Public ContactAtsushi Kamijo

Saitama Medical University Otorhinolaryngology

atkamijo@saitama-med.ac.jp049-276-1253

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026